JP2004537500A5 - - Google Patents

Download PDF

Info

Publication number
JP2004537500A5
JP2004537500A5 JP2002555834A JP2002555834A JP2004537500A5 JP 2004537500 A5 JP2004537500 A5 JP 2004537500A5 JP 2002555834 A JP2002555834 A JP 2002555834A JP 2002555834 A JP2002555834 A JP 2002555834A JP 2004537500 A5 JP2004537500 A5 JP 2004537500A5
Authority
JP
Japan
Prior art keywords
inhibitor
patient
nature
body weight
per
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002555834A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004537500A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/051339 external-priority patent/WO2002055100A2/en
Publication of JP2004537500A publication Critical patent/JP2004537500A/ja
Publication of JP2004537500A5 publication Critical patent/JP2004537500A5/ja
Pending legal-status Critical Current

Links

JP2002555834A 2000-10-20 2001-10-22 腫瘍の増殖の阻害および免疫応答の増強のための方法および組成物 Pending JP2004537500A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69360000A 2000-10-20 2000-10-20
US31818501P 2001-09-07 2001-09-07
PCT/US2001/051339 WO2002055100A2 (en) 2000-10-20 2001-10-22 Method and composition for inhibition of tumor growth and enhancing an immune response

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008262301A Division JP2009046512A (ja) 2000-10-20 2008-10-08 腫瘍の増殖の阻害および免疫応答の増強のための方法および組成物

Publications (2)

Publication Number Publication Date
JP2004537500A JP2004537500A (ja) 2004-12-16
JP2004537500A5 true JP2004537500A5 (https=) 2005-04-21

Family

ID=26981351

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002555834A Pending JP2004537500A (ja) 2000-10-20 2001-10-22 腫瘍の増殖の阻害および免疫応答の増強のための方法および組成物
JP2008262301A Pending JP2009046512A (ja) 2000-10-20 2008-10-08 腫瘍の増殖の阻害および免疫応答の増強のための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008262301A Pending JP2009046512A (ja) 2000-10-20 2008-10-08 腫瘍の増殖の阻害および免疫応答の増強のための方法および組成物

Country Status (8)

Country Link
EP (2) EP1333850B1 (https=)
JP (2) JP2004537500A (https=)
AT (1) ATE405282T1 (https=)
AU (1) AU2002243443A1 (https=)
DE (1) DE60135481D1 (https=)
DK (1) DK1333850T3 (https=)
ES (1) ES2311558T3 (https=)
WO (1) WO2002055100A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050069546A1 (en) * 2003-09-30 2005-03-31 Yaron Ilan Educated NKT cells and their uses in the treatment of immune-related disorders
SG10201404273QA (en) 2003-12-23 2014-10-30 Genentech Inc Novel anti-il 13 antibodies and uses thereof
WO2005091853A2 (en) * 2004-02-27 2005-10-06 Centocor, Inc. Methods and compositions for treating il-13 related pathologies
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
JP2008520684A (ja) 2004-11-17 2008-06-19 アブジェニックス・インコーポレーテッド Ｉｌ−１３に対する完全ヒトモノクローナル抗体
CN103143004A (zh) * 2005-02-04 2013-06-12 萨瓦克公司 存活蛋白肽疫苗
CA2914170C (en) 2006-09-08 2018-10-30 Abbvie Bahamas Ltd. Interleukin-13 binding proteins
AU2010269120B2 (en) * 2009-07-06 2015-09-24 The Australian National University Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor
TWI732259B (zh) 2010-12-16 2021-07-01 美商建南德克公司 關於th2抑制作用之診斷及治療
DE112012002748T5 (de) 2011-10-21 2014-07-31 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
ES2915378T3 (es) 2013-09-13 2022-06-22 Hoffmann La Roche Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
EP4331605A3 (en) 2013-09-13 2024-05-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
US20170165364A1 (en) * 2014-02-21 2017-06-15 Idac Theranostics, Inc. Therapeutic agent for solid cancer
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
KR20260041811A (ko) * 2023-07-12 2026-03-27 더 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신, 인코포레이티드 자연 살해 세포의 억제를 위한 조성물 및 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294322B1 (en) 1988-01-26 2001-09-25 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0656947A1 (en) * 1992-08-21 1995-06-14 Schering Corporation Human interleukin-13
US20010053371A1 (en) * 1999-01-07 2001-12-20 Waldemar Debinski Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13
JPH09150569A (ja) 1995-11-29 1997-06-10 Riso Kagaku Corp 色画像形成用シート
GB9625899D0 (en) * 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
US6013258A (en) 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
PT1141286E (pt) * 1998-12-14 2007-01-31 Genetics Inst Llc Cadeia de receptores de citocina
CN1230421C (zh) * 1999-02-10 2005-12-07 三菱制药株式会社 酰胺化合物及其药物用途
WO2001077332A2 (en) * 2000-04-07 2001-10-18 Heska Corporation Compositions and methods related to canine igg and canine il-13 receptors

Similar Documents

Publication Publication Date Title
JP2004537500A5 (https=)
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
NZ527113A (en) Rapid-onset medicament for the treatment of sexual dysfunction
WO2000064441A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
WO2002041883A3 (en) As-needed administration of tricyclic and other non-sri antidepressant drugs to treat premature ejaculation
JP2002522485A5 (https=)
TW200501983A (en) Uses of anti-insulin-like growth factor I receptor antibodies
JP2002528502A5 (https=)
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
JP2001510795A5 (https=)
JP2002524415A5 (https=)
RU2004135563A (ru) Лекарственное средство для лечения повышенной активности мочевого пузыря
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
WO2004093881A3 (en) Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors
JP2003504332A5 (https=)
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
WO2004050025A3 (en) Combination of ibuprofen and oxycodone for acute pain relief
JP2002523437A5 (https=)
CA2313270A1 (en) Use of deferiprone in treating and preventing iron-induced cardiac disease
WO2005094899A8 (en) Clusterin antisense therapy for treatment of cancer
JP2003528919A5 (https=)
IL194500A0 (en) Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application
WO2001045715A3 (en) Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain